N27 W23910A Paul Rd
Pewaukee, WI 53072 USA
Direct: (262) 347-1250
Fax: (262) 347-1251

JUL 24 2014

K133670
Page 1 of 3

NeoCoil

5. Abbreviated 510(k) Summary

5.1. Applicant
NeoCoil, LLC
N27 W23910A Paul Rd
Pewaukee, WI 53072 USA

5.2. Contact
Michael Leigh
Director, Regulatory/Quality
262-347-1250 (office)
261-347-1251 (fax)
mike.leigh@neocoil.com

5.3. Preparation Date
11/27/2013

5.4. Name of Device

- Proprietary Name: Patient Communication and Entertainment System
- Common Name: Nuclear Magnetic Resonance System
- Classification: 21 CFR 892.1000, Product Code LNH

5.5. Model Numbers

NeoCoil Model Number	NeoCoil Model Name
NC077000	Patient Communication and Entertainment System
NC078000	MR compatible Headphones
NC076000	Wireless Patient Alert

5.6. Device Description
The NeoCoil Patient Communication and Entertainment (PCE) System is intended to provide audio entertainment and facilitate communications between the patient and the operator in a Magnetic Resonance Imaging (MRI) scanner environment. The PCE System is intended to be used by healthcare professionals.

The NeoCoil Patient Communication and Entertainment System is a modular system comprised of wireless patient headphones, a remote audio data source unit, patient alert, and communications infrastructure.

5.7. Predicate Device

- Medical Visors MV100 (K103507), cleared on 02/08/2011

5.8. Comparison to Predicate
The NeoCoil Patient Communication and Entertainment System is similar in physical, performance, design and material characteristics to the legally marketed device Medical Visors MV100, K103507, as cleared on 02/08/2011.

Use of the device in conjunction with an MRI scanner is similar.

Clinical testing demonstrates that use of the NeoCoil Patient Communication and Entertainment System does not affect the safety and/or the effectiveness of the device when used as labeled.

N27 W23910A Paul Rd
Pewaukee, WI 53072 USA
Direct: (262) 347-1250
Fax: (262) 347-1251

NeoCoil

5.9. Indications for Use

The NeoCoil PCE System is intended to provide audio entertainment and facilitate patient communication in MRI environments at 3 tesla field strength and below. The product has no medical function or purpose.

5.10. Intended Use

The NeoCoil PCE System is intended to provide audio entertainment and facilitate patient communication in MRI environments. The product is not intended for medical diagnosis or treatment.

The product is intended for "MR Conditional" use in MRI environments at 3 Tesla and below. Technologist control units are intended to be used outside of the MRI scan room.

Wireless receivers are intended for use outside of the imaging field of view.

5.11. Testing

The following data has been submitted, referenced or relied on to demonstrate that the Patient Communication and Entertainment System is safe and effective. The device's performance meets the requirements of pre-defined acceptance criteria and intended uses.

Performance Testing - Bench:

Test	Pass/Fail Criteria	Result
Max B1 in first fault conditions	Pre-defined performance standards	**PASS**: Patient Communication and Entertainment System does not arc or show any signs of voltage breakdown.
Surface Temperature in normal and first fault conditions	Pre-defined performance standards	**PASS**: RF heating is not greater than 41^{o} C.
NEMA MS 6-2008	Pre-defined performance standards	**PASS**: Patient Communication and Entertainment System does not adversely impact MR image SNR and Uniformity
Coherent Noise Test	Pre-defined performance standards	**PASS**: Patient Communication and Entertainment System does not introduce image artifacts noise in center frequency range of compatible field strengths.
Noise Reduction	Pre-defined performance standards	**PASS**: >20 dBA NRR (ANSI S3.19-1974)
Quality of Service and Coexistence Test	Pre-defined performance standards	**PASS**: Patient Communication and Entertainment System provides adequate quality of service for patient communication during MRI scanning.

Published Standards Testing:

The Patient Communication and Entertainment System has been evaluated to the following standards:

N27 W23910A Paul Rd
Pewaukee, WI 53072 USA
Direct: (262) 347-1250
Fax: (262) 347-1251

NeoCoil

Standard	Purpose
IEC 60601-1	Electromechanical safety
IEC 60601-1-2	Electromagnetic Compatibility
IEC 60601-2-33	Electromechanical safety for magnetic resonance equipment
ISO 10993-1	Biocompatibility
NEMA MS6	Characterization of Special Purpose Coils for Diagnostic Magnetic Resonance Images

Performance Testing - Clinical:
Clinical data submitted exhibits a mix of pulse sequences and imaging options in the axial, sagittal and coronal planes as recommended in the FDA guidance, *Guidance for the Submission Of Premarket Notifications for Magnetic Resonance Diagnostic Devices*, issued November 14, 1998.

No adverse events were reported during clinical performance testing; the Patient Communication and Entertainment System does not adversely affect MR image production in the worst-case environment.

5.12. Conclusion

This submission demonstrates that the Indications for Use associated with the Patient and Communication Entertainment System are as safe and effective as the predicate device, Medical Visors MV1000 K103507, as cleared on 02/08/2011. As such, the Patient Communications and Entertainment system is equivalent to its predicate, Medical Visors MV100 (K103507), cleared on 02/08/2011.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-0002

NeoCoil, LLC
% Mr. Michael Leigh
Director, Regulatory/Quality
N27 W23910A Paul Road
PEWAUKEE WI 53072

July 24, 2014

Re: K133670
Trade/Device Name: Headphones, Patient Alert, Standalone Interface
Regulation Number: 21 CFR 892.1000
Regulation Name: Magnetic resonance diagnostic device
Regulatory Class: II
Product Code: LNH
Dated: June 20, 2014
Received: June 23, 2014

Dear Mr. Leigh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,



for

Janine M. Morris
Director
Division of Radiological Health
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement on last page.

510(k) Number *(if known)*

K133670

Device Name

Patient Communication and Entertainment System

Indications for Use *(Describe)*

The NeoCoil PCE system is intended to provide audio entertainment and facilitate patient communication in MRI environments at 3 tesla field strength and below.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) *(Signature)*

Michael D. O'Hara

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."